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diminished Neural Processing of Aversive and
ewarding Stimuli During Selective Serotonin
euptake Inhibitor Treatment
iara McCabe, Zevic Mishor, Philip J. Cowen, and Catherine J. Harmer
ackground: Selective serotonin reuptake inhibitors (SSRIs) are popular medications for anxiety and depression, but their effectiveness,
articularly in patients with prominent symptoms of loss of motivation and pleasure, has been questioned. There are few studies of the
ffect of SSRIs on neural reward mechanisms in humans.
ethods: We studied 45 healthy participants who were randomly allocated to receive the SSRI citalopram, the noradrenaline reuptake
nhibitor reboxetine, or placebo for 7 days in a double-blind, parallel group design. We used functional magnetic resonance imaging to
easure the neural response to rewarding (sight and/or flavor of chocolate) and aversive stimuli (sight of moldy strawberries and/or an
npleasant strawberry taste) on the final day of drug treatment.
esults: Citalopram reduced activation to the chocolate stimuli in the ventral striatum and the ventral medial/orbitofrontal cortex. In
ontrast, reboxetine did not suppress ventral striatal activity and in fact increased neural responses within medial orbitofrontal cortex to
eward. Citalopram also decreased neural responses to the aversive stimuli conditions in key “punishment” areas such as the lateral
rbitofrontal cortex. Reboxetine produced a similar, although weaker effect.
onclusions: Ourfindings are thefirst to show that treatmentwith SSRIs candiminish theneural processingofboth rewardingandaversive
timuli. The ability of SSRIs to decrease neural responses to rewardmight underlie the questioned efficacy of SSRIs in depressive conditions
haracterized by decreasedmotivation and anhedonia and could also account for the experience of emotional blunting described by some
atients during SSRI treatment.ey Words: Antidepressants, depression, fMRI, reward, SSRI, ven-
ral striatum
elective serotonin reuptake inhibitors (SSRIs) have become
the mainstay of pharmacologic treatment for depressive
and anxiety disorders and hold a preeminent position in
he global antidepressant market (1). SSRIs have achieved this
redominance through their reasonable tolerance and broad
ange of clinical indications; however, concerns about their
fficacy and behavioral toxicity persist (2,3). For example, al-
hough SSRIs appear effective at attenuating pervasive negative
ffect, a key clinical feature of anxiety and depressive disorders
4), their ability to improve diminished positive affect by reliev-
ng symptoms of low energy, decreased motivation, and anhe-
onia has been questioned (5). Related to this are reports that
ome patients associate SSRI treatment with an experience of
motional blunting through which emotional responses to both
versive and pleasurable experiences are diminished (6,7). Ex-
erimental studies in animals and humans indicate that serotonin
athways exert an inhibitory influence over neural systems
ediating both positive and negative affective processes (8).
hus, increases in serotonin function produced by SSRIs could
roduce a form of “emotional constraint” in which the salience of
oth rewarding and aversive stimuli is lost (8). In view of the
idespread use of SSRIs, such an effect could have considerable
ersonal and social implications.
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oi:10.1016/j.biopsych.2009.11.001Investigating the effect of SSRIs on emotional responses in
depressed patients is difficult because loss of pleasure (anhedo-
nia) may persist even during clinical remission (9). In addition,
modest degrees of emotional blunting might be difficult for
individuals to detect or report subjectively. In this study, we used
functional magnetic resonance imaging (fMRI) to measure the
neural basis of primary rewarding and aversive stimuli in healthy
volunteers who received short-term treatment with the widely
used SSRI citalopram. As a comparison, we studied the effects of
a similar course of treatment with reboxetine, an antidepressant
drug that selectively inhibits reuptake of the catecholamine
neurotransmitter noradrenaline. Clinically, catecholamine-po-
tentiating agents such as reboxetine have been suggested by
some to be more effective at treating symptoms such as anhe-
donia in depression (5,10) and produce more robust effects in
reinforcement paradigms in animal experimental studies than
SSRIs (11). We therefore predicted that citalopram treatment
would lower the neural response to both rewarding and aversive
stimuli in the key reward circuitry of ventral striatum, medial
prefrontal, and orbitofrontal cortices in which we and others
have shown to be sensitive to unconditioned rewarding and
aversive stimuli (12,13) whereas we expected that neural re-
sponses to rewarding stimuli would be preserved following
reboxetine treatment.
Methods andMaterials
Participants
Forty-five healthy volunteers were randomized to receive 7
days oral treatment with citalopram (20 mg/day, n  15),
reboxetine (4 mg twice daily, n  15), or placebo (n  15) in a
double-blind between-groups design. Medication was taken
twice a day, once in the morning and once in the evening, to
maintain blinding. Ethical approval was provided by the Oxford
Research Ethics Committee B, and written informed consent was
BIOL PSYCHIATRY 2010;67:439–445
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wbtained from all participants before screening and after a
omplete description of the study was given. Exclusion criteria
or all subjects were current or past Axis 1 disorder on the
tructured Clinical Interview for DSM-IV (14) and any contrain-
ications to MRI (e.g., pacemaker, mechanical heart valve, hip
eplacement, metal implants).
None of the participants took current medication apart from
he contraceptive pill. Before drug administration and to ensure
roup matching, baseline information was collected using the
eck Depression Inventory (15), State-Trait Anxiety Inventory
16), the Fawcett-Clarke Pleasure Scale (17), and the Snaith-
amilton Pleasure Scale (18). The participants also completed a
chocolate questionnaire” to measure liking, craving, and fre-
uency of eating chocolate (19) and the Eating Attitudes Test
uestionnaire, which measures attitudes to food (20). Body mass
ndex (BMI) was also calculated for each volunteer. To assess the
ffects of the treatment, the following questionnaires were taken
efore and after the treatment; visual analogue scales of happi-
ess, sadness, anger, disgust, alertness, and anxiety, and the
tate-Trait Anxiety Inventory (16) (Table 1).
verall Design
We compared brain responses to reward -related and aversive
timuli across the three drug groups. Each of the following
onditions were applied nine times in a randomized order (Table
1 in Supplement 1): chocolate in the mouth, chocolate picture,
hocolate in the mouth with chocolate picture, strawberry in the
outh, strawberry picture, strawberry in the mouth with straw-
erry picture. Subjective effects of the stimuli were measured by
sychophysical ratings of “pleasantness,” “intensity,” and “want-
ng” made on every trial by the subjects during the fMRI
cquisition. The participants were instructed not to eat chocolate
or 24 hours before the scan and to eat only a small lunch on the
ay of scanning. Mood state was recorded on the study day with
he Beck Depression Inventory (15).
timuli
Stimuli were delivered to the subject’s mouth through three
eflon tubes (one for the tasteless rinse control described later,
ne for chocolate taste, and one for strawberry taste); the tubes
ere held between the lips. Each tube was connected to a
eparate reservoir through a syringe and a one-way syringe
ctivated check valve (Model 14044-5, World Precision Instru-
able 1. Group Demographic and Psychosocial Measures
easure
Citalopram
(n 15)
Reboxetine
(n 15)
Placebo
(n 15)
ge, years 24.8 (4.8) 25.1 (4.2) 25.2 (5)
ex (M/F) 7/8 7/8 7/8
DI 2.5 (3.1) 2.21 (2.8) 1.2 (1.3)
rait 43 (5.5) 32.3 (7.3) 31.7 (4.8)
CPS 127 (13) 138.2 (14) 136.6 (14)
HAPS 22.5 (4.5) 21.9 (4.7) 20.4 (5.5)
MI 23.7 (3.6) 21.6 (2.2) 24 (2.8)
AT 4.7 (5) 3 (3) 4.5 (4.2)
hocolate Craving 6.4 (1.8) 5.9 (2.1) 4.7 (2)
hocolate Liking 8 (1.5) 8.2 (1.43) 8.3 (1.4)
hocolate Frequent Eating 1.06 (.3) .82 (.45) .78 (.33)
Data are mean (SD) unless otherwise noted. One-way analyses of vari-
nce; p .07.
BDI, Beck Depression Inventory; BMI, Body Mass Index; EAT, Eating Atti-
udes Test questionnaire; FCPS, Fawcett Clarke Pleasure Scale; SHAPS,
naith-Hamilton Pleasure Scale.
ww.sobp.org/journalments, Stevenage, United Kingdom), which allowed .5 mL of any
stimulus to be delivered manually at the time indicated by the
computer. The chocolate was formulated to be liquid at room
temperature, with a list of the six stimulus conditions described
in Table S1 in Supplement 1. A control tasteless solution .5 mL of
a saliva-like rinse solution (25  103 mol/L KCl and 2.5  103
mol/L NaHCO3 in distilled H2O) was used between trials (Table
S1 in Supplement 1), which when subtracted from the effects of
the other stimuli allowed somatosensory and any mouth move-
ment effects to be subtracted from the effects produced by the
other oral stimuli (21,22). This allowed the taste, texture, and
olfactory areas to be shown independently of any somatosensory
effects produced by introducing a fluid into the mouth (21–24).
The aversive stimulus was a strawberry drink (Rosemount Phar-
maceuticals, Leeds, United Kingdom), which was rated as intense
as the chocolate but unpleasant in valence (13). Both the liquid
chocolate and the strawberry had approximately the same sweet-
ness and texture, which enabled them to pass freely through the
Teflon delivery tubes.
Experimental Procedure
At the beginning of each trial, one of the six stimuli chosen by
random permutation was presented. If the trial involved an oral
stimulus, this was delivered in a .5-mL aliquot to the subject’s
mouth. At the same time, at the start of the trial, a visual stimulus
was presented, which was the picture of chocolate, of moldy
strawberries, or a gray control image of approximately the same
intensity. The image was turned off after 7 sec, at which time a
small green cross appeared on a visual display to indicate to the
subject to swallow what was in the mouth. After a delay of 2 sec,
the subject was asked to rate each of the stimuli for “pleasant-
ness” on that trial (with  2 being very pleasant and 2 very
unpleasant), for “intensity” on that trial (0 to 4), and for
“wanting” ( 2 for wanting very much, 0 for neutral, and 2 for
very much not wanting). The ratings were made with a visual
analog scale in which the subject moved the bar to the appro-
priate point on the scale using a button box. After the last rating,
the gray visual stimulus indicated the delivery of the tasteless
control solution, which was also used as a rinse between stimuli;
this was administered in exactly the same way as a test stimulus,
and after 7 sec the subject was cued by the green cross to
swallow. The tasteless control was always accompanied by the
gray visual stimulus. On trials in which only the picture of
chocolate was shown, there was no rinse, but the gray visual
stimulus was shown to allow an appropriate contrast as de-
scribed subsequently. There was then a 2-sec delay period that
allowed for swallowing followed by a 1-sec gap until the start of
the next trial. A trial was repeated for each of the six stimulus
conditions shown in Table S1 in Supplement 1, and the whole
cycle was repeated nine times. The instruction given to the
subject was (on oral delivery trials) to move the tongue once as
soon as a stimulus or tasteless solution was delivered to distribute
the solution around the mouth to activate the receptors for taste
and smell and then to keep still for the remainder of the 7-sec
period until the green cross was shown, when the subject could
swallow. This procedure has been shown to allow taste effects to
be demonstrated clearly with fMRI, using the procedure of
subtracting any activations produced by the tasteless control
from those produced by a taste or other stimulus (21–24).
fMRI Scan
The experimental protocol consisted of an event-relatedinterleaved design using in random permuted sequence the six
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C. McCabe et al. BIOL PSYCHIATRY 2010;67:439–445 441timuli as described above and shown in Table S1 in Supplement
. Images were acquired with a 3.0 T Varian/Siemens whole-
ody scanner at the Centre for Functional Magnetic Resonance
maging at Oxford, where T2*-weighted echo planar imaging
EPI) slices were acquired every 2 sec (repetition time  2).
maging parameters were selected to minimize susceptibility and
istortion artifact in the orbitofrontal cortex (25). Coronal slices
25) with in-plane resolution of 3  3 mm and between plane
pacing of 4 mm were obtained. The matrix size was 64  64,
nd the field of view was 192  192 mm. Acquisition was carried
ut during the task performance, yielding 972 volumes in total. A
hole brain T2*-weighted EPI volume of these dimensions and
n anatomic T1 volume with coronal plane slice thickness 3 mm
nd in-plane resolution of 1.0  1.0 mm was also acquired.
MRI Analysis
The imaging data were analyzed using SPM5 (http://www.fil.
on.ucl.ac.uk/spm/). Preprocessing of the data used SPM5 re-
lignment, reslicing with sinc interpolation, normalization to the
ontreal Neurological Institute coordinate system, and spatial
moothing with a 6-mm full-width-at-half-maximum isotropic
aussian kernel and global scaling (26). The time series at each
oxel were low-pass filtered with a hemodynamic response
ernel. Time series nonsphericity at each voxel was estimated
nd corrected for (27), and a high-pass filter with a cut-off period
f 128 sec was applied. In the single-event design, a general
inear model was then applied to the time course of activation in
hich stimulus onsets were modeled as single impulse response
unctions and then convolved with the canonical hemodynamic
esponse function (HRF) (28). Linear contrasts were defined to
est specific effects. Time derivatives were included in the basis
unctions set. Following smoothness estimation (29), linear con-
rasts of parameter estimates were defined to test the specific
ffects of each condition with each individual dataset. Voxel
alues for each contrast resulted in a statistical parametric map of
Table 2. Regions Showing Significant Effect of Treatme
Brain Region
Chocolate in Mouth: Placebo Citalopram
Ventral Striatum
Sight of Chocolate: Placebo Citalopram
Mid OFC
Ventral Striatum
VMPFC/MOFC
Chocolate in Mouth with Sight of Chocolate: Reboxetin
MOFC/Frontal Pole
Strawberry in Mouth: Placebo Citalopram
Insula
Strawberry in Mouth: Placebo Reboxetine
LOFC
Sight of Moldy Strawberries: Placebo Citalopram
LOFC/Anterior Insula
Insula
Strawberry in Mouth with Sight of Strawberry: Placebo
LOFC/Anterior Insula
p value clusters whole-brain fully corrected (family-
Cing, cingulate; LOFC, lateral orbitofrontal cortex; M
tal cortex; VMPFC, ventral medial prefrontal cortex.
aFalse discovery rate small volume correction.the corresponding t statistic, which was then transformed into the
unit normal distribution (SPM Z). The statistical parametric maps
from each individual data set were then entered into second-
level, random-effects analyses accounting for both scan-to-scan
and subject-to-subject variability. To assess the between-group
differences for each condition, a repeated-measures factorial
design was used with Group as the between-group factor (three
levels: citalopram, reboxetine, and placebo) and condition as the
within-subject factor (six levels) (30). This was followed up with
one-sample t tests to examine simple main effects of group.
SPM converts the t statistics to Z scores. For the between-
group analyses, we report p values for each cluster within
regions of a priori hypotheses (see Introduction), thresholded at
p  .001 and fully corrected for the number of comparisons
(resels) in the entire brain volume (“whole-brain” multiple
comparisons for which p .05 family-wise error. We report small
volume corrections for brain regions in which we had an a priori
hypothesis (see Introduction) as follows: pregenual cingulate
cortex [4 30 2], ventral striatum (10 6 2) and medial
prefrontal cortex [0 54–12] (13,31). Peaks within 20 mm of these
and that had a p value of at least p  .002 uncorrected in the
whole brain analysis and with a cluster threshold of 30 contigu-
ous voxels (k  30) had applied small volume (false discovery
rate) corrections for multiple comparisons (29) with a radius
corresponding to the full width at half maximum of the spatial
smoothing filter used. Plots of parameter estimates are extracted
using the volume of interest eigen variates tool in SPM5 with a
sphere of 6 mm around the peak voxel identified from the
significant contrast of interest in the key areas described in our a
priori hypotheses—namely, the ventral striatum and orbitofrontal
cortex. For illustration purposes only, Wake Forest University
Pick Atlas (32) was used to display activations (http://www.
fmri.wfubmc.edu/cms/software). Coordinates of the activations
are listed in the stereotactic space of the Montreal Neurological
Institute’s ICBM152 brain (Tables 2 and 3; Table S3 in Supple-
ment 1).
Each Condition Relative to Placebo
MNI Coordinates
Z Score
Significance
(p Value)x y z
6 10 4 4.28 .001
8 14 4 4.22 .001a
26 32 10 4.22 .003
6 14 8 3.79  .001
2 44 14 3.51 .009
lacebo
10 42 30 3.01 .05a
40 6 8 4.41  .001
46 34 6 4.39 .05
32 26 4 5.12 .002
40 2 8 4.2 .03
alopram
30 26 2 4.22  .001
rror).
ontreal Neurological Institute; MOFC, medial orbitofron-nt on
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wesults
emographic Details andMood Ratings
There were no significant differences among the three groups
s determined by one-way analyses of variance (ANOVAs) for
ge, sex, body mass index, chocolate liking, and attitudes toward
ood (Eating Attitudes Test), p  .07 (Table 1). There were no
ignificant differences between the three groups as determined
y one-way ANOVAs for measures of anhedonia (Snaith-Hamil-
on Pleasure Scale, Fawcett-Clarke Pleasure Scale) or mood
Beck Depression Inventory), p  .1 (Table 1). There were no
ignificant differences between the three groups over the 7-day
xperimental period on visual analogue scales (alertness, dis-
ust, drowsiness, anxiety, happiness, nausea, and sadness) as
etermined by repeated-measures ANOVAs, p  .1 (Table S2 in
upplement 1).
atings of Stimuli
Ratings of pleasantness, intensity, and wanting for the stimuli
ere obtained during the scanning on each trial for every
ondition. All subjects rated the strawberry picture and taste as
npleasant and the chocolate stimuli as pleasant. Using repeated-
easures ANOVA with Ratings as a first factor with three levels
pleasantness, intensity, and wanting) and Condition as a second
actor with six levels (Table S1 in Supplement 1 for the six
able 3. Regions Showing Direct Comparison of Treatment Effects
rain Region
MNI
Coordinates
Z score
Significance
(p Value)x y z
hocolate in Mouth: Reboxetine
Citalopram
Ventral striatum 6 12 4 4.64 .07
Putamen 22 14 10 4.29 .005
Caudate 10 22 2 4.85 .001
MOFC 2 32 24 3.44 .01a
ight of Chocolate:
Ventral striatum 8 10 4 4.02 .001
Insula 38 6 6 5.02 .001
Pregenual cing 0 48 2 4.66 .001
Amygdala 18 8 16 4.47 .006
trawberry in Mouth:
Insula 38 8 12 4.52 .001
p value clusters whole brain fully corrected (family-wise error).
MNI,MontrealNeurological Institute;MOFC,medial orbitofrontal cortex;
ing, cingulate.
aFalse discovery rate small volume correction.ww.sobp.org/journalcondition levels), there was no significant main effect of Group
[F (1,42)  .149, p  .95] or Condition by Group interaction,
[F (1,42)  .32, p  .96; Table S4 in Supplement 1].
fMRI Responses
Table S3 in Supplement 1 provides a summary of the results
for each contrast across all subjects to indicate the main effect of
task. Tables 2 and 3 provide a summary of the results of the
interaction with Group.
Main Effect of Task
As expected, the taste stimuli of chocolate and strawberry
activated an overlapping region of the anterior insula (i.e., the
primary taste cortex) in all subjects (Table S3 in Supplement 1).
The rewarding stimuli chocolate taste and chocolate picture
activated reward-relevant circuitry, including the ventral stria-
tum, the cingulate cortex, and the mid-orbitofrontal cortex. By
contrast, the unpleasant stimuli of strawberry taste and sight of
the moldy strawberries activated areas involved in aversive
processing, including the lateral orbitofrontal cortex extending
into the insula cortex and the caudate (Table S3 in Supplement 1).
Chocolate Reward: Sight and Taste
The citalopram group, compared with placebo and rebox-
etine, showed less blood oxygen level–dependent (BOLD) acti-
vation to the sight and taste of chocolate in areas known to play
a key role in reward, including the ventral striatum (Figure 1A
and 1B) and the ventral medial orbitofrontal cortex. This activa-
tion was not in an area of signal dropout, confirmed by overlying
the activation cluster on individual EPI data. There were no areas
where the citalopram group showed greater BOLD activation
relative to placebo or reboxetine for any of the conditions
(Tables 2 and Table 3). Relative to placebo, the reboxetine group
had enhanced BOLD activation to the chocolate in the medial
orbitofrontal/frontal pole region (Figure 2A and 2B).
Aversive Strawberry: Sight and Taste
The citalopram group relative to placebo showed less BOLD
activation to the sight and taste of strawberry in areas known to
play a key role in processing aversive stimuli, including the
lateral orbitofrontal cortex and insula as illustrated in Figure 3A
and 3B and Figure 4A and 4B. Relative to placebo, the reboxetine
group also had less BOLD activation to the unpleasant straw-
berry taste in the lateral orbitofrontal cortex (Table 2).
Discussion
Our findings are the first to show that 7-days treatment with
an SSRI diminishes the neural processing of both rewarding and
Figure 1. (A) Sight of chocolate condition (placebo [Plac]
citalopram [Cital]). Axial, sagittal, and coronal image of
increased ventral striatal activation in the placebo group
compared with the citalopram group ([6 14 8], z 
3.79, p  .001, family-wise error corrected). Paramenter
estimates from 6-mm sphere centered at 14 6 8 for
citalopram, reboxetine (Rebox), and placebo.
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C. McCabe et al. BIOL PSYCHIATRY 2010;67:439–445 443versive stimuli. This is consistent with the proposal that SSRI
reatment might produce a general constraint of emotional
esponse (8) rather than simply decreasing the emotional impact
f aversive stimuli. Such an effect could underlie the postulated
odest antidepressant efficacy of SSRIs in patients whose de-
ression is characterized by loss of motivation and pleasure (4) in
hom abnormalities in neural reward mechanisms have been
emonstrated in functional imaging studies (33,34). It has been
uggested that such patients may benefit more from the use of
atecholamine-potentiating antidepressants (4,10), which agrees
ith the effects of reboxetine seen here to increase some aspects
f reward processing.
As expected, citalopram treatment had less BOLD activation
o the aversive stimuli, consistent with the ability of SSRIs to
iminish negative affect across a range of psychiatric disorders
4,10). Interestingly, reboxetine, seemed to have less effect on
versive responses than citalopram. This is in line with clinical
bservations that catecholamine-potentiating agents appear less
ffective than SSRIs at reducing distress and negative affect and
ave less overall utility, for example, in the management of
nxiety disorders (5,35).
The ability of SSRIs to limit the neural activation to reward
ay therefore support the clinical reports that SSRI treatment
s associated not only with experiences of diminished negative
ffect (less sadness, less ability to cry) (36) but in some patients
lso with diminished positive affect (decreased sexual pleasure
nd feelings of joy) (6,7). In SSRI-treated clinical populations
ho report diminished positive affect, it is difficult to disentangle
ossible effects of subclinical depressive symptomatology or trait
isturbances in reward mechanisms from those of concomitant
SRI treatment. For example, we have shown that unmedicated,
linically remitted depressed patients demonstrate blunted stria-
igure 3. (A) Sight of moldy strawberries condition (pla-
ebo [Plac] citalopram [Cital]): axial, sagittal, and coro-
al image of increased lateral orbitofrontal cortex activa-
ion in the placebo group compared with the citalopram
roup ([32 26 4], z  5.12, p  .002, family-wise error
orrected). (B) Parameter estimates from 6-mm sphere
entered at 32 264 for citalopram, reboxetine (Rebox),
nd placebo.tal responses to chocolate reward (13). However, the present
study of healthy subjects indicates that SSRI treatment can itself
attenuate the neural processing of reward as well as that of
aversive stimuli. It is conceivable, however, that in acutely
depressed patients, SSRI treatment might produce a different
effect on the neural processing of reward than that seen in
healthy volunteers. Further studies are necessary to explore this
possibility.
The time course of our study (7 days) was limited compared
with the duration of clinical treatment with antidepressants, and
it is therefore also relevant to study the effect of SSRIs on the
neural basis of reward after longer treatment periods. However,
a meta-analysis of clinical trials has shown that, relative to
placebo, SSRIs significantly decrease depressive symptomatol-
ogy after 1 week of treatment (37), and indeed the effect size of
active treatment relative to placebo is numerically greater during
the first week of therapy than in subsequent weeks. Further, we
have demonstrated in healthy volunteers that 7-day treatment
with both citalopram and reboxetine produces positive biases in
measures of emotional perception and memory, suggesting that
therapeutically relevant changes in neuropsychological function
are indeed apparent during the first week of antidepressant
administration (38).
Our participants showed no subjective sense of impaired
reward to chocolate administration as judged by their ratings of
“wanting” or “liking,” even though the corresponding neural
response was substantially diminished. This suggests that im-
paired neural processing of reward does not necessarily become
the subject of conscious awareness, although it could still
presumably influence behavior. For example, longer-term SSRI
treatment is associated with significant weight gain in clinical
populations (39) which would not be predicted from the known
Figure 2. (A) Chocolate in the mouth with the sight of
chocolate (reboxetine [Rebox]  placebo [Plac]): axial,
sagittal, and coronal image of increased medial orbito-
frontal cortex/frontal pole activation in the reboxetine
group compared with the placebo ([10 4230], z 3.01,
p  .05 false discovery rate small volume corrected). (B)
Parameter estimates from6-mmsphere centered at 10 42
30 for citalopram (Cital), reboxetine, and placebo.www.sobp.org/journal
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wffects of serotonin on appetite (40). However, using an exper-
mental paradigm similar to our own, Stice et al. (41) showed an
ssociation between obesity and decreased neural response in
triatum to food reward, suggesting that obese subjects might
vereat to compensate for the reward deficit. A similar mecha-
ism could explain SSRI-induced weight gain during continued
reatment.
Our findings indicate that the undoubtedly clinically useful
ffects of SSRIs in a wide range of psychiatric conditions char-
cterized by painful and disabling negative affect (42,43) may
eed to be balanced against their inhibitory effects on the neural
esponses to reward. As noted earlier, it could be the case that in
epressed patients, in whom neural responses to reward appear
o be lowered before treatment, SSRIs might in some way
roduce different effects on reward processing than those seen
ere in healthy participants. Larger studies in depressed patients
nd healthy control subjects, employing a within-subject design
pre- and posttreatment) are necessary to test this proposal.
Another relevant point is that although our data agree with
lausible neurobiological hypotheses concerning the differential
oles of serotonin and catecholamines in antidepressant action
4,10), clinical studies in patients have not revealed consistent
ifferences between serotonin and noradrenergic potentiating
ntidepressant in their ability to treat specific symptom domains
n depressed patients (44). In addition, the important functional
nteractions between serotonin and catecholamine pathways
eans that effects of pharmacologically selective agents will not
e confined to a single neurotransmitter system (45). Neverthe-
ess, recent pooled analyses suggest that although the cat-
cholaminergic antidepressant bupropion may be slightly less
ffective than SSRIs in treating depression associated with high
evels of anxiety, it appears superior in resolving symptoms of
leepiness and fatigue (46,47). Finally, although SSRI treatment
as been associated with emotional blunting in some patients
6,40), it is not established that the incidence of this phenomenon
s greater with SSRIs than with other antidepressants acting
hrough contrasting pharmacologic mechanisms.
If it is, in fact, the case that the inhibitory effect of SSRI
reatment on neural responses to reward limits the potential
ffectiveness of SSRIs in the management of depression, it might
e possible to improve the efficacy of SSRIs through the recruit-
ent of pharmacologic mechanisms that enhance neural re-
ponses to reward as well as diminishing responses to aversive
timuli. A straightforward way to achieve this could be the use of
erotonin and noradrenaline reuptake inhibitors (SNRIs) such as
uloxetine and venlafaxine. Another strategy would be to add a
rug such as bupropion to SSRI therapy. However, although
hese strategies may produce some benefits over SSRI mono-
ww.sobp.org/journaltherapy (48,49), overall their effectiveness appears modest
(50,51). In this respect, it is not clear that noradrenergic or
dopaminergic potentiation has the ability to “reverse” the major
inhibitory effect of SSRI treatment on neural reward mechanisms
demonstrated by our study. Further investigations examining the
effects on reward of SNRIs as well as SSRI combination treat-
ments are needed to address this question.
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